Abstract:As a safe and natural "capsule," plants have several advantages over mammals and microorganisms for the production of oral vaccines. In this study, we innovatively utilized the transmembrane region of the pea Translocase of chloroplast 34 (TOC34) protein to display two subunit vaccines, capsid protein VP2 of Porcine parvovirus (PPV) and the heat-labile enterotoxin B (LTB) of Escherichia coli, on the surface of chloroplasts. Unlike microbial display techniques, chloroplast display circumvents antigen degradation in the stomach while retaining the size characteristic of microorganisms. Additionally, a co-expressed peptide adjuvant, antimicrobial peptide protegin-1 (PG1), was used to enhance the strength of oral immunization. Immunohistochemistry and trypsin digestion of chloroplast surface proteins confirmed the successful localization of both antigens on the chloroplast surface. In stable transgenic tobacco plants, the expression level of VP2-TOC34 ranged from 0.21 to 6.83 μg/g FW, while LTB-TOC34 ranged from 2.42 to 10.04 μg/g FW. By contrasting the digestive characteristics of plant materials with different particle sizes, it was observed that plant materials with diameters around 1 mm exhibited more prominent advantages in terms of chloroplast release and antigen exposure compared to both larger and smaller particles. Oral immunization resulted in significantly increased levels of specific IgG and secretory IgA in the mice compared to the control, with similar effects observed between the groups receiving oral immunization alone and those receiving a combination of initial injection and subsequent oral immunization. Challenge experiments further demonstrated the effective protection against infection in mice using this approach. These findings highlight the potential of chloroplast display technology for the development of effective oral vaccines.

Immunological aspects of using plant cells as delivery vehicles for oral vaccines

Plant-made vaccine antigens and biopharmaceuticals

Bio-Engineered Plant-produced Antigens, Self-Administered for Oral Vaccination: A Cottage Industry for Vaccines for Less Affluent Nations?

Advancedoral vaccine delivery strategies for improving the immunity.

Advanced Oral Vaccine Delivery Strategies for Improving the Immunity

Induction of Oral Tolerance with Transgenic Plants Expressing Antigens for Prevention/Treatment of Autoimmune, Allergic and Inflammatory Diseases

Research Advances on Transgenic Plant Vaccines

Research advances on transgenic plant vaccines.

Edible Plant-Derived Extracellular Vesicles for Oral mRNA Vaccine Delivery

Integrating plant molecular farming and materials research for next-generation vaccines

Plant-Derived Human Vaccines: Recent Developments

Chloroplast display of subunit vaccines and their efficacy via oral administration

Oral Delivery of mRNA Vaccine by Plant-Derived Extracellular Vesicle Carriers

Recent Development and Future Prospects of Plant-Based Vaccines

Accumulation of recombinant SARS-CoV spike protein in plant cytosol and chloroplasts indicate potential for development of plant-derived oral vaccines.

Recent Advances and Safety Issues of Transgenic Plant-Derived Vaccines.

Use of GFP to investigate expression of plant-derived vaccines.

Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

Plant glycoengineering for designing next-generation vaccines and therapeutic proteins

Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine

Mucoadhesive Vaccine Delivery Systems for the Oral Mucosa